Bolka Pharmaceuticals

Bolka Pharmaceuticals is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Bolka Pharmaceuticals. Bolka Pharmaceuticals is spin off company of Micar Innovation, registered in Sofia, Bulgaria. Under terms of the agreement, Micar Innovation grants Bolka Pharmaceuticals (Sofia - Bulgaria) an exclusive option to license and develop MIC4578 drugs targeting Chronic Pain disease. Bolka Pharmaceuticals capital is in the hands of Micar Innovation driven by impact and provide value to our future investors. BOLKA PHARMACEUTICALS AIM Bolka Pharmaceuticals (spin off company of Micar Innovation) is specialized in the discovery, development and commercialization of the small molecule drugs and transforming the treatment of chronic pain by advancing one of the largest, exclusively pain-focused clinical pipelines of novel, non-opioid therapies. By using structure based in silico drug design & AI (Micar21 platform) we constructed the best Chronic Pain drug candidate fast & validated. We aim to bridge the safety and efficacy gaps in current approaches to chronic pain management. The company is focused on the development of the safe non-opioid-next-generation pain killer for the patients suffering from chronic pain, cancer pain, etc. Bolka Pharmaceuticals lead drug candidate, MIC4578, is currently in the phase preclinical for the treatment of chronic pain. BOLKA PHARMACEUTICALS MISSION Chronic pain is a growing problem – not only in terms of the significant number of people that are impacted and the burden this places on our healthcare system, but also because of the abuse and addiction issues, as well as deaths, that have arisen from the high use of opioids to treat chronic pain. Our mission is to relieve the suffering associated with chronic pain by developing treatments that address the safety and efficacy gaps in the current treatment paradigm. Our broad pipeline represents our mission to tackle the problem of chronic pain head on by developing treatments that act at new or emerging pharmacological targets and delivering them in ways that best address the particular type of chronic pain. We believe that our non-opioid approaches to chronic pain treatment have the potential to provide effective therapeutic options while avoiding the abuse and addiction epidemic that has resulted from high use of opioid drugs.